This week the San Antonio Breast Cancer Symposium will take place, from 10 to 14 December 2019.
The symposium, which brings together thousands of breast cancer specialists from all over the world, aims to provide the most up-to-date information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
Several oral presentations and posters related to BIG trials and research collaborations will be presented over the course of these four days – be sure not to miss them:
- Wednesday 11/12/2019
9:30 am General Session
Interim overall survival analysis of APHINITY (BIG 4-11): A randomised multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. Piccart M
5:00 pm – 7:00 pm Poster session OT1
OT1-04-02
Positive: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (ibcsg 48-14/big 8-13). Pagani O
- Thursday 12/12/2019
04:00 pm General Session
GS4-04
Ten year results of the international breast cancer intervention study II. Cuzick J
GS4-05
Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X. To be presented by Fatima Cardoso
- Friday 13/12/2019
7:00 am – 9:00 am Poster session 4
P4-10-03
The genomic landscape of male breast cancers using the Oncomine Comprehensive Assay for actionable mutations. Bayani J
5:00 pm – 7:00 pm Poster session 5
P5-02-01
Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group Study. Acs B
P5-12-01
Sole (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (bc): final analysis and sole estrogen substudy (sole-est). Jerusalem G
